Back to mobile site
Get it on Google Play

TG Therapeutics reports Phase 1 azer-cel data in progressive MS

October 23, 2026 10:55 AM EDT Send to a Friend
TG Therapeutics, Inc. (NASDAQ: TGTX) presented initial results from a Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational allogeneic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login